Profile data is unavailable for this security.
About the company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
- Revenue in USD (TTM)49.94bn
- Net income in USD11.76bn
- Incorporated1996
- Employees76.06k
- LocationNovartis AGLichtstrasse 35BASEL 4056SwitzerlandCHE
- Phone+41 613241111
- Fax+41 613247826
- Websitehttps://www.novartis.com/
More ▼
Mergers & acquisitions
| Acquired company | NOVN:SWX since announced | Transaction value |
|---|---|---|
| Mariana Oncology Inc | 5.20% | 1.75bn |
| IFM Due Inc | 6.95% | 835.00m |
| Cytokinetics Inc | 3.62% | -- |
| Calypso Biotech BV | 3.62% | 425.00m |
| SanReno Therapeutics | 4.27% | -- |
Data delayed at least 15 minutes, as of Nov 22 2024 16:37 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co | 47.44bn | -7.26bn | 119.40bn | 34.10k | -- | 6.96 | 40.65 | 2.52 | -3.60 | -3.60 | 23.38 | 8.45 | 0.513 | 3.97 | 5.12 | 1,391,056.00 | -7.84 | 3.05 | -10.45 | 3.76 | 75.87 | 76.13 | -15.28 | 7.69 | 1.09 | 11.30 | 0.7431 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Pfizer Inc | 60.11bn | 4.27bn | 145.36bn | 88.00k | 34.48 | 1.57 | 12.98 | 2.42 | 0.7438 | 0.7399 | 10.57 | 16.29 | 0.2767 | 1.60 | 4.71 | 683,079.60 | 1.98 | 8.20 | 2.39 | 10.40 | 70.82 | 69.34 | 7.16 | 22.68 | 0.729 | -- | 0.4225 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 32.53bn | 4.23bn | 158.32bn | 26.70k | 37.69 | 21.03 | 16.15 | 4.87 | 7.82 | 7.82 | 60.33 | 14.00 | 0.3587 | 2.08 | 4.83 | 1,218,502.00 | 4.66 | 10.36 | 5.87 | 13.06 | 60.48 | 75.41 | 13.00 | 26.51 | 0.9553 | 2.62 | 0.8892 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Novartis AG (ADR) | 49.94bn | 11.76bn | 231.42bn | 76.06k | 18.17 | 4.81 | 13.79 | 4.63 | 5.74 | 8.56 | 24.35 | 21.67 | 0.4619 | 2.16 | 6.76 | 656,612.80 | 10.87 | 8.53 | 16.86 | 11.23 | 74.99 | 72.93 | 23.54 | 22.68 | 0.9002 | 14.72 | 0.4248 | 67.20 | 7.57 | 0.2779 | 41.64 | -7.71 | 0.7808 | 3.57 |
| Merck & Co Inc | 63.17bn | 12.15bn | 250.89bn | 72.00k | 20.80 | 5.64 | 15.27 | 3.97 | 4.77 | 4.77 | 24.95 | 17.58 | 0.5634 | 2.39 | 5.80 | 877,416.70 | 10.85 | 7.70 | 14.19 | 10.29 | 76.59 | 72.26 | 19.25 | 15.03 | 1.15 | 24.33 | 0.4611 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 55.53bn | 5.08bn | 312.70bn | 50.00k | 61.73 | 51.84 | 23.14 | 5.63 | 2.87 | 2.87 | 31.32 | 3.41 | 0.3972 | 4.31 | 4.85 | 1,110,660.00 | 3.67 | 6.55 | 5.09 | 8.40 | 67.25 | 69.74 | 9.24 | 16.46 | 0.5419 | 7.88 | 0.9213 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
Data as of Nov 23 2024. Currency figures normalised to Novartis AG's reporting currency: US Dollar USD
2.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 30 Sep 2024 | 12.22m | 0.56% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 12.01m | 0.55% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 7.28m | 0.33% |
| Loomis, Sayles & Co. LPas of 30 Sep 2024 | 5.77m | 0.26% |
| Franklin Mutual Advisers LLCas of 30 Sep 2024 | 4.28m | 0.20% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 3.64m | 0.17% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 3.54m | 0.16% |
| Managed Account Advisors LLCas of 30 Sep 2024 | 3.17m | 0.15% |
| Parametric Portfolio Associates LLCas of 30 Sep 2024 | 3.06m | 0.14% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 2.53m | 0.12% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
